![]() Epidemiology considerations should include real-world questions of “concomitant conditions” that may come into play…who are the subpopulations commonly found in this group-additional diseases or conditions (renal, hepatic, cardiovascular, etc.) that impact the patient, treatment decisions, or healthcare system capabilities. I’ve arrived at an answer to the question-but because of the ever-changing nature of Market Access, I am open to everyone’s input to correct my answer or expand on it, but please don’t just dismiss it! Clearly, Market Access positioning and the value story to support a product in the US begins with the AMCP Format for Formulary Submissions (now in version 4.0)…but I offer the following “high altitude” view in answer to the question, “What are the building blocks of that value story?”Įpidemiology: The value of any product begins with a comprehensive understanding of the disease: pathophysiology and presentation risk factors diagnostic pathways scope and impact in the target population practical impact on healthcare systems and current clinical options. I have found answers as simple as “In the US, just build your value story with the Academy of Managed Care Pharmacy’s (AMCP) dossier template.” Or as complex as “Building a Market Access value story is finding the nexus of disease, product, economics, models and markets.” The answer must lie somewhere in between those two: using a “template” and “finding a nexus.” The irony is that Market Access is evolving so rapidly that I settled on a definition that was equally changeable…my definition is more vague than I wanted it to be: it includes three terms-dynamic, ever-growing, ever-changing-that guarantee constant change.īut I believe in the foundation of my definition: “Market Access is a process for building a value story.” Logically, the next question is, “What are the building blocks of that value story…how do we construct the story?” Trying to see into the future, I’ve been reading, searching, studying, and talking with people to define the term and predict where this area of the healthcare industry, Market Access, is heading. ![]() ![]() “Market Access is a dynamic process for building an ever-growing, ever-changing value story that validates a product’s price/position in healthcare practice”-at least, that’s what I claimed in my last article.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |